More DCAT Value Chain Insights

In-depth analysis of the critical issues impacting the full spectrum of the pharmaceutical manufacturing value chain.

As 2018 comes to a close, what are key trends and emerging areas of interest for the pharmaceutical industry overall and in manufacturing? From new business models in healthcare delivery, to drug pricing, to digital transformation, to new...

Refining business strategies to respond to changing market conditions is a constant in any industry, including the pharmaceutical industry. As the industry enters the final month of 2018, which pharmaceutical company CEOs have made the mark thus...

What were the top developments shaping the pharmaceutical industry overall and the pharma manufacturing value chain in 2018? Takeda’s pending $62-billion acquisition of Shire, Cambrex’s $425-million acquisition of Halo Pharmaceuticals, a...

Emerging markets represent both opportunity and challenges for pharmaceutical companies. Risk management is an important component of any sourcing program, but with rising trade tensions and geopolitical uncertainty, managing supply lines and...

The pharmaceutical industry as a whole historically has had weaker working-capital performance comparative to other industries, but it is a key strategic goal overall for pharma companies and for sourcing and procurement organizations to improve...

Biosimilars are a small part of the overall market for biologics, which accounted for $277 billion in sales globally in 2017 and is projected to reach $452 billion by 2022. The European Union leads with biosimilar approvals comparative to the US,...

Orphan drugs represent a niche sector in the global pharmaceutical market, but have accounted for approximately 40% of new drug approvals in the US over the past three years. Traditionally the focus of smaller innovator companies, the...

The pharmaceutical industry is on a record-setting pace for approvals of new molecular entities (NMEs) in 2018. Through early November, the FDA had approved 48 NMEs, already outpacing 2017’s recent high of 46 NME approvals and nearing the high mark...